Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Mar 3;5(3):e9515.
doi: 10.1371/journal.pone.0009515.

A scoping review of strategies for the prevention of hip fracture in elderly nursing home residents

Affiliations

A scoping review of strategies for the prevention of hip fracture in elderly nursing home residents

Anna M Sawka et al. PLoS One. .

Abstract

Background: Elderly nursing home residents are at increased risk of hip fracture; however, the efficacy of fracture prevention strategies in this population is unclear.

Objective: We performed a scoping review of randomized controlled trials of interventions tested in the long-term care (LTC) setting, examining hip fracture outcomes.

Methods: We searched for citations in 6 respective electronic searches, supplemented by hand searches. Two reviewers independently reviewed all citations and full-text papers; consensus was achieved on final inclusion. Data was abstracted in duplicate.

Findings: We reviewed 22,349 abstracts or citations and 949 full-text papers. Data from 20 trials were included: 7--vitamin D (n = 12,875 participants), 2--sunlight exposure (n = 522), 1--alendronate (n = 327), 1--fluoride (n = 460), 4--exercise or multimodal interventions (n = 8,165), and 5--hip protectors (n = 2,594). Vitamin D, particularly vitamin D(3) > or = 800 IU orally daily, reduced hip fracture risk. Hip protectors reduced hip fractures in included studies, although a recent large study not meeting inclusion criteria was negative. Fluoride and sunlight exposure did not significantly reduce hip fractures. Falls were reduced in three studies of exercise or multimodal interventions, with one study suggesting reduced hip fractures in a secondary analysis. A staff education and risk assessment strategy did not significantly reduce falls or hip fractures. In a study underpowered for fracture outcomes, alendronate did not significantly reduce hip fractures in LTC.

Conclusions: The intervention with the strongest evidence for reduction of hip fractures in LTC is Vitamin D supplementation; more research on other interventions is needed.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The potential competing interests of authors (if any) are otherwise summarized in the following sentences. A. M. Sawka, N. Ismaila, L. Thabane, M. Kastner, A. Gafni, L. J. Woodhouse, and A. Cheung have no competing interests to declare. A. Cranney has received speaker fees from Merck Frosst, Sanofi-Aventis, Procter & Gamble, and Eli Lilly. R. Crilly has been a consultant or received honoraria from Merck Frosst. J. D. Adachi has been a consultant or speaker for the following companies: Amgen, AstraZeneca, Eli Lilly, Glaxo-Smith-Kline, Merck Frosst, Novartis, Nycomed, Pfizer, Procter & Gamble, Roche, Sanofi-Aventis, Servier, Wyeth, and Bristol-Myers Squibb. J. D. Adachi has received funding for clinical trials from the following companies: Amgen, Eli Lilly, Glaxo-Smith-Kline, Merck Frosst, Novartis, Pfizer, Procter & Gamble, Sanofi-Aventis, Roche, Wyeth, and Bristol-Myers Squibb. R. J. Josse has been a consultant or received honoraria from the following companies: Procter & Gamble, Sanofi-Aventis, Eli Lilly, Novartis, Amgen, and Servier. A. Papaioannou has been a consultant for the following companies: Eli Lilly, Merck Frosst, Sanofi-Aventis, Procter & Gamble, Amgen, and Novartis. A. Papaioannou has received honoraria from the following companies: Eli Lilly, Merck Frosst, Sanofi-Aventis, Procter & Gamble, Amgen, Servier, Novartis. A. Papaioannou has received grants from the following companies: Eli Lilly, Merck Frosst, Sanofi-Aventis, Procter & Gamble, Amgen, and Novartis. None of the speakers has any stock to declare.

References

    1. Weller I, Schatzker J. Hip fractures and Alzheimer's disease in elderly institutionalized Canadians. Ann Epidemiol. 2004;14(5):319–324. - PubMed
    1. Chandler JM, Zimmerman SI, Girman CJ, Martin AR, Hawkes W, et al. Low bone mineral density and risk of fracture in white female nursing home residents. J Amer Med Assoc. 2000;284(8):972–977. - PubMed
    1. Singh S, Sun H, Anis AH. Cost-effectiveness of hip protectors in the prevention of osteoporosis related hip fractures in elderly nursing home residents. J Rheumatol. 2004;31(8):1607–1613. - PubMed
    1. Lauritzen JB Hip fractures. Epidemiology, risk factors, falls, energy absorption, hip protectors, and prevention. Dan Med Bull. 1997;44(2):155–168. - PubMed
    1. Cumming RG. Nursing home residence and risk of hip fracture. Am J Epidemiol. 1996;143(12):1191–1194. - PubMed

Publication types